By Business/Source
Currency:EUR
2025/Q3
Stock NameRevenueRatio
Research and development of PRAME-directed immunotherapies for the treatment of cancer5.19M100.00%
By Country/Region
Currency:EUR
2024/FY
Stock NameRevenueRatio
BMS, United States78.1M50.12%
Moderna, United States62.79M40.29%
Genmab, Denmark14.95M9.59%